News | September 27, 2024
Sun Pharma presents clinical efficacy and safety data in severe dermatological conditions at 2024 EADV Congress
The company will also share results in two additional posters for deuruxolitinib
The company will also share results in two additional posters for deuruxolitinib
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
MoCRA mandates that all facilities involved in the manufacturing and processing of cosmetic products for sale in the United States
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
Subscribe To Our Newsletter & Stay Updated
